BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37446095)

  • 21. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
    Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
    BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
    Emile J; Cauquil C; Carpentier D; Routier E; Robert C
    Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
    Shindo A; Yamasaki M; Uchino K; Yamasaki M
    Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
    Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
    Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
    Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
    Hellman JB; Traynis I; Lin LK
    Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
    Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
    Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
    Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
    Hu X; Wei Y; Shuai X
    Front Immunol; 2021; 12():799077. PubMed ID: 34975911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
    Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
    Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
    Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
    J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/-associated antibodies.
    Isa M; Hongo Y; Sakamoto N; Yamazaki K; Takazaki H; Asakuma J; Ikewaki K; Suzuki K
    J Neurol Sci; 2023 Jan; 444():120528. PubMed ID: 36565689
    [No Abstract]   [Full Text] [Related]  

  • 40. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.